Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10562892
Filing Date		2005-12-29
First Named Inventor Marce		el BREEUWER
Art Unit		2676
Examiner Name		
Attorney Docket Num	ber	NL030839

	U.S.PATENTS					Remove					
Examiner Cite Initial* No Patent Number Kind Code*			Issue Date Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1	6132380		2000-10-	17	COHEN ET A	L				
	2	5239591		1993-08-	24	RANGANATH	ı				
	3	6295465	В1	2001-09-	25	SIMONETTI					
If you wis	h to a	dd additional U.S. Pater	nt citatio	n informa	tion pl	ease click the	Add button.		Add		_
			U.S.P	ATENT A	APPLK	CATION PUB	LICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Name of Patentee or Applicant		Releva		Lines where ges or Relev			
	1	20010000727	A1	2001-05-	03	DRIEHUYS E	T AL				
	2	20020095086	A1	2002-07-	18	BREEUWER					
If you wis	h to a	ldd additional U.S. Publi	shed Ap	plication	citation	n information p	please click the Ad	d button	Add		_
				FOREIG	N PAT	ENT DOCUM	IENTS		Remove		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GPR 199) Art Unit Art Unit

EP

0543468

Application Number		10562892
Filing Date		2005-12-29
First Named Inventor Marce		BREEUWER
Art Unit		2676
Examiner Name		
Attorney Docket Number		NL030839

Date Considered

	2	0543468	EP	B1	1993-05-26	KPENV		
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor	Add	
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cile Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							
	XIN YANG ET AL: Computer Aided Measurement of Local Myocardial Pertusion in MRI, IEEE September 1993, pages 365-388, XP101028735							
	NIDAL AL-SAADI, ET AL: Nontrivisive Detection of Myocardial techenia From Perfusion Reserve Based on Cardiovascuater Magnetic Resonance, Circulation 2000; 101; pages 1397-1383.							
	NORBERT WILKE, ET AL: The Myocardial Pertusion Reserve: Assessment with Multisection, Quantitative, First-Pass MR Imaging, Radiology 1967, pages 373-384.							

A1 1993-05-26 KPENV

See Kint Code of USPTO Petert Documents at year USPTO_CODY or MPEP 90104. *Enter date that issued the document, by the two letter code (WPO) Standard ST3.) **Enter price papers perior from counters, the included on the year of the register or perior for the Empirical management perior the serial remains of the peter document.

*Included Cocument by the appropriate symbols as indicated on the document under WPO Standard ST.16 if possible. **Deplicant is to place a check mark here if Empirish inauguage streathers in a standard.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10562892		
Filing Date		2005-12-29		
First Named Inventor	Marce	BREEUWER		
Art Unit		2676		
Examiner Name				
Attorney Docket Numb	er	NL030839		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the ap	ppropriate selection(s)	
---------------	----------	-------------	-------------	-----------------------	----	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Daniel J. Piotrowski/	Date (YYYY-MM-DD)	2007-07-12
Name/Print	Daniel Piotrowskii	Registration Number	42.027

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.